Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. (Nasdaq: ACRS) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule and biologic candidates for immuno-inflammatory diseases. Its pipeline includes bosakitug, an anti-TSLP antibody; ATI-052, a bispecific antibody targeting TSLP and IL-4 receptor alpha; and… From the company’s description.
Over the twelve months to Sep 30, 2026, Aclaris Therapeutics, Inc. reported revenue of $6.40M, down 59.3% from a year earlier, and a net loss of $79.63M. Operations used $75.21M in cash. In fiscal 2025, it reported revenue of $7.83M, down 58.2% from fiscal 2024, and a net loss of $64.92M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Aclaris Therapeutics, Inc. does
In the company’s own words
Aclaris Therapeutics, Inc. (Nasdaq: ACRS) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule and biologic candidates for immuno-inflammatory diseases. Its pipeline includes bosakitug, an anti-TSLP antibody; ATI-052, a bispecific antibody targeting TSLP and IL-4 receptor alpha; and the oral kinase inhibitors ATI-2138 and ATI-9494, which target ITK pathways. The company also develops lepzacitinib, a topical JAK 1/3 inhibitor, and uses its proprietary KINect platform for kinase drug discovery. Its programs address conditions including atopic dermatitis, asthma, and other inflammatory and autoimmune diseases; candidates are investigational, and Aclaris seeks third-party partners to help develop, secure approval for, or commercialize them. Aclaris licenses bosakitug and ATI-052 from Biosion for territories outside Greater China. It acquired lepzacitinib and ATI-2138 through its 2017 acquisition of Confluence. Aclaris reports a single operating and reportable segment and had no product sales in 2025. Its website is https://www.aclaristx.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WAYNE, PA
- Fiscal year end
- December
- CIK
- 1557746
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Aclaris Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Aclaris Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Aclaris Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Aclaris Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Aclaris Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”